Pages that link to "Q36240860"
Jump to navigation
Jump to search
The following pages link to MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status (Q36240860):
Displaying 50 items.
- A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature (Q21560781) (← links)
- Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions (Q26795767) (← links)
- Oligodendroglioma: pathology, molecular mechanisms and markers (Q27002448) (← links)
- The somatic genomic landscape of glioblastoma (Q28300185) (← links)
- Platform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral Decomposition (Q29300552) (← links)
- Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial (Q30836702) (← links)
- The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. (Q34061985) (← links)
- Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma (Q34098218) (← links)
- MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study (Q34166477) (← links)
- Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region (Q34168829) (← links)
- Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial (Q34500050) (← links)
- Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme. (Q35079153) (← links)
- Genome-wide methylation analyses in glioblastoma multiforme (Q35107175) (← links)
- The future of high-grade glioma: Where we are and where are we going (Q35114090) (← links)
- Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma (Q35128022) (← links)
- Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment (Q35787908) (← links)
- MGMT testing allows for personalised therapy in the temozolomide era. (Q35827916) (← links)
- From the core to beyond the margin: a genomic picture of glioblastoma intratumor heterogeneity. (Q35828508) (← links)
- DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. (Q36042596) (← links)
- Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design (Q36096097) (← links)
- Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison (Q36182479) (← links)
- Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact (Q36272539) (← links)
- Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice (Q36344709) (← links)
- Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them? (Q36542980) (← links)
- Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients (Q36552755) (← links)
- Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. (Q36618241) (← links)
- Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma. (Q36645979) (← links)
- Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma (Q36650859) (← links)
- Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. (Q36951069) (← links)
- Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective (Q37021557) (← links)
- Personalized treatment strategies in glioblastoma: MGMT promoter methylation status (Q37221207) (← links)
- MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples (Q37342829) (← links)
- Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients (Q37526270) (← links)
- A 4-miRNA signature predicts the therapeutic outcome of glioblastoma (Q37564551) (← links)
- Influence of promoter/enhancer region haplotypes on MGMT transcriptional regulation: a potential biomarker for human sensitivity to alkylating agents (Q37616073) (← links)
- EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma (Q37660295) (← links)
- Genetic and epigenetic stability of oligodendrogliomas at recurrence (Q37684236) (← links)
- MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry (Q38044236) (← links)
- Molecular neuro-oncology in clinical practice: a new horizon (Q38125031) (← links)
- MGMT testing--the challenges for biomarker-based glioma treatment (Q38218848) (← links)
- Molecular prognostic factors in glioblastoma: state of the art and future challenges (Q38233134) (← links)
- Predictive biomarkers investigated in glioblastoma. (Q38237337) (← links)
- Glioblastoma: pathology, molecular mechanisms and markers (Q38460865) (← links)
- Diagnostic, prognostic and predictive relevance of molecular markers in gliomas (Q38461565) (← links)
- Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification (Q38504172) (← links)
- Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas (Q38684835) (← links)
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study (Q38816272) (← links)
- Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. (Q38919700) (← links)
- The Role of Molecular Diagnostics in the Management of Patients with Gliomas (Q38921975) (← links)
- Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity (Q38951877) (← links)